LifeDNA Competitors

We are the curious. Ancestry®, the global leader in family history and consumer genomics, connecting everyone with their past so they can discover, preserve, and share their unique family stories. With our unparalleled collection of more than 65 billion records from 88 countries, over 3 million subscribers and over 27 million people in our growing DNA network, customers can discover their family story and gain a new level of understanding about their lives. Over the past 40 years, we’ve built trusted relationships with millions of people who have chosen us as the platform for discovering, preserving and sharing the most important information about themselves and their families. Ancestry has over 1,300 employees in locations across the globe. Our headquarters is in Lehi, Utah and our global offices are located in Dublin, Ireland; Paris, France; London, England; Sydney, Australia; and Grafing, Germany. We are committed to our location flexible work approach, allowing you to work from where you want — in an office or from home or a hybrid of both (subject to location restrictions and roles that are required to be in the office). We will continue to hire and promote beyond the boundaries of our office locations, to enable broadened possibilities for employee diversity. We’re passionate about using technology to create simple, useful, and delightful experiences that connect families and have accelerated product innovation to enable everyone to discover, craft and connect around their family story. Ancestry is continually looking for talented, hard-working and curious individuals who are passionate about bringing this mission to life. Sound like you? Join the curious. Visit https://careers.ancestry.com

23andMe Research Institute is a nonprofit medical research organization that enables people everywhere to access their genetic information, learn about themselves and participate in the world's largest crowdsourced research initiative. The Institute aims to be the world's most significant contributor to scientific advancement, uniting people with the common goal of improving health and deepening our understanding of DNA — the code of life.

Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California.